Literature DB >> 15867586

Increased transduction of human intestinal epithelial cells by adenoviral vectors in inflammatory bowel disease.

Phyllissa Schmiedlin-Ren1, Filippos Kesisoglou, John A Mapili, Sayed E Sabek, Jeffrey L Barnett, William D Chey, Blake Roessler, Ellen M Zimmermann.   

Abstract

BACKGROUND: Delivery of genes encoding anti-inflammatory proteins has been proposed as a strategy for the treatment of inflammatory bowel disease (IBD). The goal of this study was to assess the ability of a standard adenoviral vector to transfect epithelial cells in intestinal explants from patients with IBD compared with controls.
METHODS: Endoscopic colon biopsies obtained from patients with no history of IBD and endoscopically normal colon (n = 4), patients with a history of ulcerative colitis (UC; n = 5), and patients with a history of Crohn's disease (CD; n = 3) were placed in explant culture and exposed to an adenoviral vector carrying the nuclear targeted beta-galactosidase reporter gene.
RESULTS: X-Gal staining showed that the total number of transduced cells per square millimeter was greater in UC explants than in controls (mean, 11.3 versus 0.9 blue nuclei/mm, respectively; P < 0.02) and that the frequency of epithelial cell transduction was greater in UC explants than in controls (86% versus 47% of explants, respectively; P = 0.01). Transduction of mature columnar surface epithelial cells occurred exclusively in UC and CD explants and was not seen in controls. Attenuated epithelial cells at sites of tissue damage or ulceration showed increased transduction compared with mature columnar epithelial cells (62% versus 19% of occurrences, respectively; P < 0.0001).
CONCLUSIONS: We conclude that intestinal epithelial cells from IBD patients are more readily transfected by standard adenoviral vectors than are those from control patients. These results suggest that targeting genes to inflamed intestine through the luminal route may be possible.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15867586     DOI: 10.1097/01.mib.0000158535.54428.a5

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  4 in total

1.  Gene and cell therapy based treatment strategies for inflammatory bowel diseases.

Authors:  Sander van der Marel; Anna Majowicz; Sander van Deventer; Harald Petry; Daniel W Hommes; Valerie Ferreira
Journal:  World J Gastrointest Pathophysiol       Date:  2011-12-15

2.  Effective in vivo and ex vivo gene transfer to intestinal mucosa by VSV-G-pseudotyped lentiviral vectors.

Authors:  Hiroshi Matsumoto; Takahiro Kimura; Kazunori Haga; Noriyuki Kasahara; Peter Anton; Ian McGowan
Journal:  BMC Gastroenterol       Date:  2010-05-11       Impact factor: 3.067

3.  SLC26A3 (DRA) prevents TNF-alpha-induced barrier dysfunction and dextran sulfate sodium-induced acute colitis.

Authors:  Xiangming Ding; Dongxiao Li; Mengke Li; Han Wang; Qin He; Yunwu Wang; Hongbing Yu; Dean Tian; Qin Yu
Journal:  Lab Invest       Date:  2018-01-12       Impact factor: 5.662

Review 4.  Targeting the gastrointestinal tract with viral vectors: state of the art and possible applications in research and therapy.

Authors:  Roeland Buckinx; Jean-Pierre Timmermans
Journal:  Histochem Cell Biol       Date:  2016-09-24       Impact factor: 2.531

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.